We have outlined the properties of TB-500 and its research applications in the following paragraphs. Studies have suggested that Thymosin beta-4 may be a healing protein speculated to regenerate and repair tissue throughout the organism. According to research, TB-500 is a synthetic form of Thymosin beta-4, whose potential is under contemporary investigation and evaluation. Some of the research hypotheses associated with the peptide have been:
- A possible function in healing soft tissue injuries.
- A possible function in promoting cardiovascular function.
- A possible function as an agent in the context of inflammatory disorders.
In this guide, we summarize the research conducted on the properties of TB-500 peptides and highlight the information that researchers need to know when working with this peptide in research settings. Please note that none of the substances mentioned in this article have not been approved for human or animal consumption and should, therefore, not be acquired or utilized by unlicensed individuals. Research peptides are currently available only to researchers, scientists, or academics interested in employing them in investigations set in contained environments such as laboratories. This article serves educational purposes only.
TB-500 Peptide: What is it?
Thymosin beta-4 is a naturally occurring peptide composed of 43 amino acids. TB-500 peptide is an iteration of Thymosin beta-4 that was manufactured synthetically. White blood cells have a high concentration of thymosin beta-4, which is considered to contribute to the creation of blood cells while also expediting the processes of wound healing and tissue repair. Thymosin beta-4 is found in practically every kind of known cell and tissue.
Research conducted in the first stages of the healing process suggested that thymosin beta-4 may play a significant part in protecting wounded cells and tissues against developing microorganisms and inflammation. As a result of its potential to upregulate actin, increase angiogenesis, and mobilize stem and progenitor cells, it may reduce the number of myofibroblasts present in wounds and the amount of scarring that takes place.
TB-500 Peptide Potential
Vascular regeneration: TB-500 peptide has been hypothesized to accelerate the pace at which new blood cells, blood vessels, and tissue fibers are generated, potentially facilitating the acceleration of the healing process while minimizing the amount of scarring.
Cardiovascular health: Research conducted in 2016 theorized that TB-500 peptide may have enhanced left ventricular function in mice with myocardial infarction. The study’s authors speculated that the peptide may aid in mediating cardioprotection.
Healing of wounds: A 2005 Phase I clinical study suggested that TB-500 peptide may have repaired wounded tissues and played a “key role” in the healing of cutaneous and corneal wounds.
Dry-eye disease: In a clinical ocular experiment, six research models with non-healing neurotrophic keratitis wounds appeared to have exhibited a “significant reduction” in eye pain and seemed “completely healed” after Tβ4 eye drops two to six times per day for 28 days.
Anti-oxidant and anti-inflammatory action: Shah et al. hypothesized that TB-500 peptide may reduce “oxidative stress, inflammation, and fibrosis” in mice with ethanol and LPS-induced liver damage.
Insulin resistance: Research conducted in 2012 has theorized that TB 500 peptide may reduce hyperglycemia and improve insulin resistance in a mouse model of type 2 diabetes mellitus (T2DM), suggesting it may be an alternative insulin sensitizer.
Hair development and growth: Research on animals has indicated that TB-500 peptide might accelerate the hair development rate in mice while encouraging cashmere production by raising the number of secondary hair follicles in cashmere goats.
Tumor-suppressing properties: Researchers asserted that mice presented with TB-500 over-expressing myeloma cells appeared to have a higher survival rate than mice presented with controls. The study’s authors have theorized that the peptide may have a “tumor suppressive function.”
TB-500 and cancer research: Huang et al. implied that TB-500 may have a role in the context of non-small cell lung cancer (NSCLC) since it seems to inhibit the proliferation of NSCLC cells by inhibiting the activation of Notch1.
Researchers interested in performing further studies to learn more about the potential of this research compound may buy TB-500 by navigating to the Biotech Peptides website, where they can also find more articles and papers about research peptides, what they are how they work and what their research properties may be.
References
[i] Goldstein AL, Hannappel E, Sosne G, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. doi: 10.1517/14712598.2012.634793
[ii] Crockford D, Turjman N, Allan C, et al. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-89. doi:10.1111/j.1749- 6632.2010.05492.x.
[iii] Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-9.
[iv] Sosne G, Kleinman HK. Primary Mechanisms of Thymosin β4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries. Invest Ophthalmol Vis Sci. 2015;56(9):5110-7. doi:10.1167/iovs.15-16890.
[v] Shah R, Reyes-Gordillo K, Cheng Y, et al. Thymosin β4 Prevents Oxidative Stress, Inflammation, and Fibrosis in Ethanol- and LPS-Induced Liver Injury in Mice. Oxid Med Cell Longev. 2018;2018:9630175. doi:10.1155/2018/9630175
[vi] Zhu J, Su LP, Ye L, Lee KO, Ma JH. Thymosin beta 4 ameliorates hyperglycemia and improves insulin resistance of KK Cg-Ay/J mouse. Diabetes Res Clin Pract. 2012 Apr;96(1):53-9. doi: 10.1016/j.diabres.2011.12.009. Epub 2012 Jan 3. PMID: 22217673.
[vii] Dai B, Sha RN, Yuan JL, Liu DJ. Multiple potential roles of thymosin β4 in the growth and development of hair follicles. J Cell Mol Med. 2021 Feb;25(3):1350- 1358. doi: 10.1111/jcmm.16241. Epub 2021 Jan 3. PMID: 33393222; PMCID: PMC7875905.
[viii] Caers J, Hose D, Kuipers I, et al. Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma. Haematologica. 2010;95(1):163–167. doi:10.3324/haematol.2009.006411
